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Since the report of the first patient in Brazil with
Coronavirus disease 2019 (COVID-19), in São Paulo city, on
February 26, 2020, there have been concerns about COVID-19
in select patient populations, mainly solid organ trans-
planted patients, who are normally maintained in an immu-
nosuppressed state to avoid organ rejection. Despite the
universal knowledge that children and adolescents with
COVID-19 have milder clinical manifestations than other
groups of patients (such as those 460 years of age) (1),
we have always dedicated great care to the pediatric patients
in the early and late postoperative period after a liver trans-
plant. We have further enhanced our perioperative care with
special emphasis on diagnosing possible COVID-19 or any
associated morbidity. Our concern was based on the rising
occurrence of COVID-19 with severe acute respiratory syn-
drome (SARS) leading to death in some cases in São Paulo,
the most populous city of Latin America.
Our hospital is one of the most important reference centers
for the treatment of pediatric liver diseases and pediatric
transplantation in Latin America, with extensive experience
in patients with acute liver failure (2). Our liver transplanta-
tion program started in September 1989 (3). The main
objective of this presentation is to report our experience of
detecting COVID-19 in liver transplant patients in our
ambulatory outpatient clinic.
Since the start of our program, 845 children have under-
gone liver transplant as a treatment for various terminal liver
diseases at our institution: 395 were living donor liver
transplants and 447 were from cadaveric donors. The main
indication for liver transplant were biliary atresia and
cirrhosis (387 patients), other forms of cirrhosis including
autoimmune diseases (133 patients), fulminant hepatic fail-
ure (121 patients), and diverse causes, including diffuse
hepatoblastoma needing chemotherapy and metabolic dis-
eases (204 patients). All patients received immunosuppres-
sive drugs that consisted of a calcineurin inhibitor, either
cyclosporine, from 1989 to 2000, or tacrolimus, from 2001 to
present day. Treatment with methylprednisolone (20 mg/kg)
was initiated from the moment of graft reperfusion and then
gradually tapered in the postoperative period to a main-
tenance dosage of 0.5 to 1.0 mg/kg of body weight/day.
A third drug, mycophenolate mofetil (MMF), was adminis-
tered solely in cases of repeated episodes of rejection or
refractory rejection. MMF or sirolimus was also used as a
single-drug immunosuppressant for patients with deteriora-
tion of renal function. Additionally, almost all patients
received an anti-hypertensive drug, such as an angiotensin-
converting enzyme inhibitor (ACEi).
The patients were routinely examined in the ambulatory
clinic or were assessed telephonically. We presently have
approximately 190 liver transplant patients who are con-
stantly being followed-up at our ambulatory clinic. Those
who turned adults are currently being followed-up at an
adult service.
Immediately after the first report of COVID-19, in March
and April, our patients were routinely checked for any
clinical signs or symptoms suggestive of COVID-19. During
this period, six patients presented with symptoms consistent
with mild upper airway infection and fever; however, among
the tested patients, all but one had a negative RT-PCR test.
None of the patients, including the patient who tested
positive for SARS-CoV-2, developed clinical pulmonary
disease. Also, during this period, 169 non-transplant children
in our institution, suspected of having COVID-19, were
tested for the virus, and 13 (7.7%) had a positive test. All of
them presented with mild clinical manifestations and one of
them died secondary to a serious genetic syndrome. Finally,
for a better understanding of the major differences between
children and adults, we were notified that during the same
period, 1,251 adult patients were referred to Hospital das
Clinicas da Faculdade de Medicina da Universidade de
São Paulo and 208 of them were admitted to the intensive
care unit.
The first important consideration about the current report
is that in a group of patients who theoretically should be
at high risk for developing COVID-19 and SARS, none of
them had the disease or suffered from complications. Our
patients have many risk factors, including immunosuppres-
sion with multiple drugs, autoimmune disease, unknown
immunological disturbances as seen in some cases of fulmi-
nant hepatic failure, and chemotherapy in patients with
hepatoblastoma. In general, patients, need treatment with anDOI: 10.6061/clinics/2020/e1986
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ACEi to counteract hypertension caused by immunosuppres-
sion treatment with calcineurin inhibitors, a treatment con-
sidered to be a risk factor for developing SARS COVID-19 in
adult patients (4).
The current report concurs a recent letter by D’Antica from
Lombardy (Italy), who reported a similar experience with a
group of 700 liver transplant children. D’Antica concluded
that ‘‘immunosuppressed patients are not at increased risk
for severe pulmonary disease when compared to the general
population. Children under the age of 12 do not develop
coronavirus pneumonia, regardless of their immune status,
although they get infected and can, therefore, spread the
infection.’’ Also, a conclusion was mentioned as part of a
guideline published on May 1st, 2020, in the UK National
Institute for Health and Care Excellence, where stated,
‘‘COVID-19 usually causes a mild, self-limiting illness in
children and young people, even in those who are immuno-
compromised’’ (5). Based on these conclusions from Europe
and our initial experience described here, we can affirm that
during the present coronavirus outbreak there are no reasons
to postpone life-saving treatments such as liver transplanta-
tion in children.
Finally, some important points need clarification. We
have seen a decrease in the supply of cadaveric donors
during this pandemic. Should we, therefore, perform living
donor liver transplantations? What if healthy young parents
of children with terminal liver diseases are available for
liver donation? In extreme situations, such as fulminant
hepatic failure in children, should we use organs from
SARS-CoV-2 positive donors or should we transplant to
SARS-CoV-2 positive recipients? There is evidence that
the SARS-CoV-2 virus will not be completely eradicated for
a while, and we hope that the scientific community will
help us to find ways to make correct decisions in such
difficult situations.
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